PDTD: a web-accessible protein database for drug target identification
© Gao et al; licensee BioMed Central Ltd. 2008
Received: 14 August 2007
Accepted: 19 February 2008
Published: 19 February 2008
Target identification is important for modern drug discovery. With the advances in the development of molecular docking, potential binding proteins may be discovered by docking a small molecule to a repository of proteins with three-dimensional (3D) structures. To complete this task, a reverse docking program and a drug target database with 3D structures are necessary. To this end, we have developed a web server tool, TarFisDock (Tar get Fis hing Dock ing) http://www.dddc.ac.cn/tarfisdock, which has been used widely by others. Recently, we have constructed a protein target database, P otential D rug T arget D atabase (PDTD), and have integrated PDTD with TarFisDock. This combination aims to assist target identification and validation.
PDTD is a web-accessible protein database for in silico target identification. It currently contains >1100 protein entries with 3D structures presented in the Protein Data Bank. The data are extracted from the literatures and several online databases such as TTD, DrugBank and Thomson Pharma. The database covers diverse information of >830 known or potential drug targets, including protein and active sites structures in both PDB and mol2 formats, related diseases, biological functions as well as associated regulating (signaling) pathways. Each target is categorized by both nosology and biochemical function. PDTD supports keyword search function, such as PDB ID, target name, and disease name. Data set generated by PDTD can be viewed with the plug-in of molecular visualization tools and also can be downloaded freely. Remarkably, PDTD is specially designed for target identification. In conjunction with TarFisDock, PDTD can be used to identify binding proteins for small molecules. The results can be downloaded in the form of mol2 file with the binding pose of the probe compound and a list of potential binding targets according to their ranking scores.
PDTD serves as a comprehensive and unique repository of drug targets. Integrated with TarFisDock, PDTD is a useful resource to identify binding proteins for active compounds or existing drugs. Its potential applications include in silico drug target identification, virtual screening, and the discovery of the secondary effects of an old drug (i.e. new pharmacological usage) or an existing target (i.e. new pharmacological or toxic relevance), thus it may be a valuable platform for the pharmaceutical researchers. PDTD is available online at http://www.dddc.ac.cn/pdtd/.
Until 2000, only ~500 drug targets had been reported , among which only 120 drug targets are actually marketed . The completion of human genome and numerous pathogen genomes suggests that there are 30,000 to 40,000 genes and at least the same number of proteins, and many of these proteins are potential targets for drug discovery. It has been estimated that there are more than 2,000 potential drug targets with at least one drug candidate in clinical trial [2, 3]. This is a reservoir for drug discovery and target identification. However, how to extensively utilize this source is a challenge. Expressing all these proteins and screening compounds against the corresponding models constructed based on the proteins is extremely unpractical, because it is intolerably expensive and time-consuming. Recent promising advancement in docking-based virtual screening has demonstrated the efficiency of this approach in discovering lead (active) compounds [4, 5]. On the other hand, reverse (or inverse) docking approaches have become promising computational tools to find the probable target proteins for active compounds, natural products or old drugs [6–10]. Both these two researches need the information of target proteins, in particular the information of structures and active sites. However, such information of most drug targets is dispersedly deposited in the literatures or other databases like Protein Data Bank (PDB). Therefore, it is in dire need of a database containing comprehensive information of the potential target proteins.
Recently, some notable efforts have been made to partially satisfy this requirement. The Therapeutic Target Database (TTD) is one such example , which provides information about the known therapeutic targets, disease conditions and the corresponding drugs. DrugBank is a bioinformatics/cheminformatics resource that combines detailed drug data with comprehensive drug target information . A number of ligand-protein interaction databases have also emerged including LigBase , PDBsite , SitesBase , MSDsite , PDB-Ligand  and AffinDB . Unfortunately, these databases were not specifically designed for discovering new leads by using virtual screening approaches and new targets by using reverse docking. They also cannot be used to figure out specific pharmaceutical information related to the secondary effects of an old drug (i.e. new pharmacological usage) or an existing target (i.e. new pharmacological or toxic relevance). Ideally, a target database may provide not only abundant information about the potential target proteins such as 3D structures, binding (active) sites, biological (pharmacological) functions, related diseases, but also appropriate computational tools to mine the information about targets. Herein, we present a web-accessible protein database, PDTD (P otential D rug T arget D atabase). Integrated with our reverse docking server, TarFisDock , PDTD is a valuable platform for target identification.
Construction and content
The target proteins in PDTD were selected from scientific literatures [1, 19–21] and several online databases such as TTD , DrugBank  and Thomson Pharma . Since PDTD is designed to search the probable binding proteins for new active compounds or existing drugs by using reverse docking, it only contains the proteins with known 3D structures determined experimentally by the X-ray crystallographic or NMR methods. The coordinates of proteins were isolated from the PDB. Since not all PDB structures are of equal quality, a protein structure is selected according to the following criteria when it has several redundant records in PDB: (i) select the structure without mutation and missing residues around the active site; (ii) select the structure with high resolution; (iii) select the structure complexed with ligand. For each selected protein in PDTD, amino acid residues within 6.5 Å around the bound ligand were used to define the binding (active) site. A PDB entry could contain data on a number of binding sites. If so, a separate entry was generated in the PDTD to accommodate each of the sites. HETATM records in PDB files were used to define the ligands. PDB and mol2 files of each protein were also stored in the structural sub-database. All kinds of structures for a drug target can be visualized using the "Jmol" JAVA applet .
According to therapeutic areas, the drug targets may be categorized into 14 types (Figure 2b). It is convenient for users to custom a special list when they predict potential binding targets for small molecules using TarFisDock. Among targets having explicit therapeutic functions, the targets related neoplastic disease are most populated, following are hormones and hormones antagonists related targets. Targets related to viral infections are also major contributors in PDTD. The distribution of biochemical classification is shown in Figure 2c, indicating that PDTD mainly consists of enzymes, receptors, ion channels, transporters, nuclear receptors, binding protein, structural proteins, signaling proteins, factors, regulators and hormones. The targets which can not be assigned into any of these biochemical classes are grouped into an "unknown" class. The selected drug targets are enriched in enzymes (80.2%). G-protein coupled receptors (GPCR) and other receptors which account for most drug targets seldom have crystal structures, resulting that the ratio of receptor targets in PDTD is only 4.2%.
Utility and Discussion
Web interface: query, download and exploration
All the data can be accessed and retrieved directly via the web browser, PDTD consists of a classification table and a keyword search box. The user can search a drug target manually from the classification table, or automatically by using the keyword search function, such as PDB ID, target name, or disease. Every target has its own result page containing comprehensive information including PDB ID, target name, target category, related disease, its structure, and active site. The PDTD was carefully annotated according to information found in the PDB, UniProt , KEGG  and Enzyme Structures Database . PDTD also provides hyperlinks to other databases like TTD and DrugBank, which allow easy navigation for more information about target structure, source and function (See Links to other databases). The related structures for each drug target can be downloaded freely from the detailed page by clicking on "MORE" button. Furthermore, user can download the classified target structures and all target files from the "Download" page.
Also, users can customize the list of drug targets in which they want to perform reverse docking process to predict the potential binding targets for any small molecule, which to our knowledge is not provided by other public websites. Consequently, TarFisDock will output the list of results with binding poses of molecules against each targets, along with corresponding information, disease, annotation and links to other databases, which are also presented (See the Applications below).
In bringing together the reverse docking server TarFisDock , PDTD has been widely used to identify binding proteins for small molecule. The binding proteins for several molecules have been verified through bioassay and crystal structure determination for target-ligand complexes . In general, one drug molecule may interact with several targets including targets associated with side effect (toxicity). TarFisDock provides multiple options for selecting protein targets. These clues are useful for further experimental test in discovering new pharmacological efficacy or toxicity for an existing drug. In general, combining with PDTD, TarFisDock web sever is a convenient tool for "fishing" the target proteins of small molecules, the user just inputs the structure of querying compound and customizes a target list from PDTD (a list of all the targets is recommended). The results can be downloaded in the form of mol2 file with the binding pose of each compound and a list of potential binding targets according to their ranking scores.
In addition, benchmark searches for the old version of PDTD (698 entries) were performed using TarFisDock taking vitamin E, an anti-oxidant, and 4H-tamoxifen, an anti-cancer agent as probes . In this study, similar benchmark searches for the current version of PDTD (1186 entries) have been carried out. For vitamin E, eight (12 entries) of the twelve experimentally verified targets fall into the top 10% candidates picked up from the PDTD by the TarFisDock program. For 4H-tamoxifen, five (14 entries) of the eleven experimentally confirmed targets appear amongst the top 10% of the TarFisDock predicted candidates. In addition, the PDTD was searched by the TarFisDock using N-trans-caffeoyltyramine (compound 1), an active natural product discovered by anti-H. pylori screening in our lab, as a probe in the previous research . Homology search revealed that, among the fifteen candidates discovered by reverse docking, diaminopimelate decarboxylase (DC) and peptide deformylase (PDF) are possible binding proteins of compound 1. Enzymatic assay demonstrated compound 1 and its derivative compound 2 are the potent inhibitors against the H. pylori PDF (Hp PDF) with IC50 values of 10.8 and 1.25 μM, respectively. X-ray crystal structures of Hp PDF and the complexes of Hp PDF with 1 and 2 were determined, indicating that these two inhibitors bind well with the Hp PDF binding pocket . To exemplify the applications of PDTD combining with TarFisDock, the brief results of these three benchmark examples have been uploaded to the PDTD homepage under the "Benchmark" option.
Links to other databases
General links are given to related drug and target information with other databases [11, 12]. Each data in PDTD is linked to the Protein Data Bank, DrugBank, there are also hypertext links to UniProt , Kegg  and Enzyme Structures Database  for further structural and functional information.
In summary, PDTD is a comprehensive, web-accessible database of drug targets, which focuses on those drug targets with known 3D-structures. By far, PDTD has collected >1100 entries covering >800 known and potential drug targets from the Protein Data Bank. PDB structure, mol2 file and active site information of each drug target were extracted from the crystal structure, and all the information can be viewed with molecular visualization tools and can be downloaded freely by users. Drug targets of PDTD were categorized by two criteria: therapeutic areas and biochemical criteria. Each target was carefully annotated by browsing several databases, such as DrugBank, TTD, and UniProt. All these information were stored in informatics sub-database, which was associated to structural sub-database with a relational database. Users can also use our reverse docking program to search PDTD for finding the possible binding protein(s) of a small molecule.
One drug molecule may interact with several targets including targets associated with side effect (toxicity). By searching PDTD, TarFisDock may provide multiple options of the binding proteins for a small molecule. These clues are useful for further experimental test in discovering new targets and new pharmacological efficacy or toxicity for an existing drug. Thus, combining with TarFisDock, PDTD is a good web-accessible protein database for identifying drug targets and for discovering new usages of old drugs [27, 28]. The user just inputs the structure of querying compound and customizes a target list from PDTD (a list of all the targets is recommended), TarFisDock may provide possible binding proteins of the compound. The results can be downloaded in the form of mol2 file with the binding pose of each compound and a list of potential binding targets according to their ranking scores.
PDTD will be updated continuously. We intend to classify the drug targets according more completely to their biological functions, which will be achieved by integrating and/or linking PDTD with other bioinformatics databases. For example, links can be directed to the databases of SOURCE  and Gene Ontology  for more descriptions of functional annotations, ontologies, and gene expression data.
Availability and requirements
PDTD is freely available for academic user at http://www.dddc.ac.cn/pdtd. To download the files of PDTD, users must complete a simple registration process and agree not to republish the data without explicit permission. Users are invited to contact us through the 'Contact' link and to participate in the user forum at http://www.dddc.ac.cn/tarfisdock/forum/.
We thank all the colleagues in Drug Discovery and Design Center for their contributions in literature searching and necessary dealing with files. The work was partly supported by the Special Fund for Major State Basic Research Project (grant 2002CB512802), the National Natural Science Foundation of China (grants 20721003 and 10572033), and the 863 Hi-Tech Program of China (grant 2007AA02Z304). HL was also sponsored by the Shanghai Postdoctoral Scientific Program.
- Drews J: Drug discovery: a historical perspective. Science 2000, 287(5460):1960–1964. 10.1126/science.287.5460.1960View ArticlePubMedGoogle Scholar
- Hopkins AL, Groom CR: The druggable genome. Nat Rev Drug Discov 2002, 1(9):727–730. 10.1038/nrd892View ArticlePubMedGoogle Scholar
- Russ AP, Lampel S: The druggable genome: an update. Drug Discov Today 2005, 10(23–24):1607–1610. 10.1016/S1359-6446(05)03666-4View ArticlePubMedGoogle Scholar
- Kitchen DB, Decornez H, Furr JR, Bajorath J: Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 2004, 3(11):935–949. 10.1038/nrd1549View ArticlePubMedGoogle Scholar
- Sperandio O, Miteva MA, Delfaud F, Villoutreix BO: Receptor-based computational screening of compound databases: the main docking-scoring engines. Curr Protein Pept Sci 2006, 7(5):369–393. 10.2174/138920306778559377View ArticlePubMedGoogle Scholar
- Chen YZ, Zhi DG: Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Proteins 2001, 43(2):217–226. 10.1002/1097-0134(20010501)43:2<217::AID-PROT1032>3.0.CO;2-GView ArticlePubMedGoogle Scholar
- Paul N, Kellenberger E, Bret G, Muller P, Rognan D: Recovering the true targets of specific ligands by virtual screening of the protein data bank. Proteins 2004, 54(4):671–680. 10.1002/prot.10625View ArticlePubMedGoogle Scholar
- Li H, Gao Z, Kang L, Zhang H, Yang K, Yu K, Luo X, Zhu W, Chen K, Shen J, Wang X, Jiang H: TarFisDock: a web server for identifying drug targets with docking approach. Nucleic Acids Res 2006, 34(Web Server issue):W219–24. 10.1093/nar/gkl114PubMed CentralView ArticlePubMedGoogle Scholar
- Cai J, Han C, Hu T, Zhang J, Wu D, Wang F, Liu Y, Ding J, Chen K, Yue J, Shen X, Jiang H: Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: reverse docking, enzymatic assay, and X-ray crystallography validation. Protein Sci 2006, 15(9):2071–2081. 10.1110/ps.062238406PubMed CentralView ArticlePubMedGoogle Scholar
- Muller P, Lena G, Boilard E, Bezzine S, Lambeau G, Guichard G, Rognan D: In silico-guided target identification of a scaffold-focused library: 1,3,5-triazepan-2,6-diones as novel phospholipase A2 inhibitors. J Med Chem 2006, 49(23):6768–6778. 10.1021/jm0606589View ArticlePubMedGoogle Scholar
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res 2002, 30(1):412–415. 10.1093/nar/30.1.412PubMed CentralView ArticlePubMedGoogle Scholar
- Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J: DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006, 34(Database issue):D668–72. 10.1093/nar/gkj067PubMed CentralView ArticlePubMedGoogle Scholar
- Stuart AC, Ilyin VA, Sali A: LigBase: a database of families of aligned ligand binding sites in known protein sequences and structures. Bioinformatics 2002, 18(1):200–201. 10.1093/bioinformatics/18.1.200View ArticlePubMedGoogle Scholar
- Ivanisenko VA, Pintus SS, Grigorovich DA, Kolchanov NA: PDBSite: a database of the 3D structure of protein functional sites. Nucleic Acids Res 2005, 33(Database issue):D183–7. 10.1093/nar/gki105PubMed CentralView ArticlePubMedGoogle Scholar
- Gold ND, Jackson RM: SitesBase: a database for structure-based protein-ligand binding site comparisons. Nucleic Acids Res 2006, 34(Database issue):D231–4. 10.1093/nar/gkj062PubMed CentralView ArticlePubMedGoogle Scholar
- Velankar S, McNeil P, Mittard-Runte V, Suarez A, Barrell D, Apweiler R, Henrick K: E-MSD: an integrated data resource for bioinformatics. Nucleic Acids Res 2005, 33(Database issue):D262–5. 10.1093/nar/gki058PubMed CentralView ArticlePubMedGoogle Scholar
- Shin JM, Cho DH: PDB-Ligand: a ligand database based on PDB for the automated and customized classification of ligand-binding structures. Nucleic Acids Res 2005, 33(Database issue):D238–41. 10.1093/nar/gki059PubMed CentralView ArticlePubMedGoogle Scholar
- Block P, Sotriffer CA, Dramburg I, Klebe G: AffinDB: a freely accessible database of affinities for protein-ligand complexes from the PDB. Nucleic Acids Res 2006, 34(Database issue):D522–6. 10.1093/nar/gkj039PubMed CentralView ArticlePubMedGoogle Scholar
- Bonday ZQ, Dhanasekaran S, Rangarajan PN, Padmanaban G: Import of host delta-aminolevulinate dehydratase into the malarial parasite: identification of a new drug target. Nat Med 2000, 6(8):898–903. 10.1038/78659View ArticlePubMedGoogle Scholar
- Gibbs JB: Mechanism-based target identification and drug discovery in cancer research. Science 2000, 287(5460):1969–1973. 10.1126/science.287.5460.1969View ArticlePubMedGoogle Scholar
- Hardman JG, Limbird LE, Gilman AG: Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th edition. New York , McGraw-Hill ; 2001.Google Scholar
- Thomson Pharma[http://www.thomson-pharma.com]
- Jmol: an open-source Java viewer for chemical structures in 3D[http://www.jmol.org/]
- Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, Ferro S, Gasteiger E, Huang H, Lopez R, Magrane M, Martin MJ, Natale DA, O'Donovan C, Redaschi N, Yeh LS: UniProt: the Universal Protein knowledgebase. Nucleic Acids Res 2004, 32(Database issue):D115–9. 10.1093/nar/gkh131PubMed CentralView ArticlePubMedGoogle Scholar
- Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M: The KEGG resource for deciphering the genome. Nucleic Acids Res 2004, 32(Database issue):D277–80. 10.1093/nar/gkh063PubMed CentralView ArticlePubMedGoogle Scholar
- Enzyme Structures Database[http://www.ebi.ac.uk/thornton-srv/databases/enzymes/]
- O'Connor KA, Roth BL: Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov 2005, 4(12):1005–1014. 10.1038/nrd1900View ArticlePubMedGoogle Scholar
- Chong CR, Sullivan DJ Jr.: New uses for old drugs. Nature 2007, 448(7154):645–646. 10.1038/448645aView ArticlePubMedGoogle Scholar
- Diehn M, Sherlock G, Binkley G, Jin H, Matese JC, Hernandez-Boussard T, Rees CA, Cherry JM, Botstein D, Brown PO, Alizadeh AA: SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Res 2003, 31(1):219–223. 10.1093/nar/gkg014PubMed CentralView ArticlePubMedGoogle Scholar
- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000, 25(1):25–29. 10.1038/75556PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.